The drug development landscape has become increasingly complex in recent years, with evolving therapeutic pipelines, compressed timelines, supply chain challenges, and a demand for virtual and decentralized trials. These trends have been intensified by the ongoing pandemic, which is poised to be a long-term disruption. Developers need access to specialized technology and global expertise to get their drugs to market. And success rests on a fast and flexible supply chain—as well as real-time communication throughout the journey.
Whether you have a small molecule or large molecule project, we offer scalable solutions that enable you to move your molecule through each phase with efficiency and speed. Our solutions help you:
We understand the unique needs of small companies—78% of our clients are new, emerging, or mid-size pharma and bio pharma companies
Trusted global network of scientific and technical experts at more than 60 sites across 23 countries
More than 80% of our clinical supply shipments are temperature-managed
In 2022 we produced over 13.1B tablets, capsules and softgels
We understand the unique needs of small companies—78% of our clients are new, emerging, or mid-size pharma and bio pharma companies
Trusted global network of scientific and technical experts at more than 60 sites across 23 countries
More than 80% of our clinical supply shipments are temperature-managed
In 2022 we produced over 13.1B tablets, capsules and softgels
The development of your active pharmaceutical ingredient (API) can be coupled with our complete drug product services range, including pre-formulation screening, clinical development, engineered solutions, and commercial supply. At every stage, you’ll benefit from seamless collaboration among our sites, teams, scientific experts, and operations. We offer unmatched speed, quality, and efficiency.
We bring almost 50 years of contract pharmaceutical manufacturing experience, including recent knowledge gained from more than 240 successful biologic development programs. Our team can help you transform your discovery into a drug substance via a sustainable process designed to scale from preclinical development to commercial manufacture. Access our fed-batch, perfusion, and Xd™ processes technologies and purification processes leveraging single-use, disposable technologies. Plus, with the Patheon™ Quick to Clinic™ solution for biologics, we can help you go from transfection to Investigational New Drug Application (IND) in as little as 13 months, using a carefully constructed program with a tried and tested process platform supported by a high-yield and royalty-free expression system, and supply assurance to mitigate raw material sourcing risks. All are designed to balance speed and risk, setting you up for long-term commercial success.
Developing and commercializing advanced therapies—often orphan treatments for rare diseases—takes specialized knowledge and the ability to navigate a complex, continuously evolving landscape. Transition seamlessly from clinical research to commercial manufacturing and distribution by leveraging our global network of facilities and expertise as well as Patheon Translational Services, which includes custom modular biology, viral vector packaging, and cell therapy services. With more than 200 advanced therapy clinical trials, more than 60 viral vector products, and FDA- and EMA-approved chimeric antigen receptor (CAR) T-cell therapies, we are helping our clients create the first FDA-approved therapeutic cancer vaccines.
With unwavering dedication to clinical research and to serving patients around the world, we are powered by people with an exceptional commitment to delivering end-to-end, high-quality global clinical supply chain services, including decentralized trials, primary packaging, secondary packaging and labeling, label design and translation services, storage and distribution, cold-chain material, and comparator sourcing.
With industry-leading depth of expertise and resources, responsiveness, flexibility, and quality, our teams understand the approval process inside and out. We can work with you to achieve parallel active pharmaceutical ingredient (API) and finished dose development, delivering on time and right the first time. Our experience in technology transfers offers you strategic advantages as you transfer production between sites or from your sites to ours. In 2020 alone, we successfully completed more than 22 API tech transfers. Successful technology transfers can help safeguard supply, improve distribution, and reduce program costs and risks.